Data as of Dec 09
| -0.22 / -0.91%|
The 4 analysts offering 12-month price forecasts for Trinity Biotech PLC have a median target of 26.00, with a high estimate of 34.00 and a low estimate of 22.00. The median estimate represents a +8.79% increase from the last price of 23.90.
The current consensus among 5 polled investment analysts is to Buy stock in Trinity Biotech PLC. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.